A Phase I Study of Dexosome Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2005 Feb 23

PMID 15723705

Citations 511

Authors

Michael A Morse

Jennifer Garst

Takuya Osada

Shubi Khan

Amy Hobeika

Timothy M Clay

Nancy Valente

Revati Shreeniwas

Mary Ann Sutton

Alain Delcayre

Di-Hwei Hsu

Jean-Bernard Le Pecq

H Kim Lyerly

Affiliations

Soon will be listed here.

Abstract

BACKGROUND: There is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC). METHODS: This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals. RESULTS: Thirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1-2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52-665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4. CONCLUSION: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors.

Citing Articles

Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.

Global requirements for manufacturing and validation of clinical grade extracellular vesicles.

Thakur A, Rai D J Liq Biopsy. 2025; 6:100278.

PMID: 40027307 PMC: 11863704. DOI: 10.1016/j.jlb.2024.100278.

Lymph node-targeted delivery of thunb. polysaccharides for enhancing antitumor immunotherapy.

Zhang J, Liu J, Zhang H, Liu B, Li L, Li Y Mater Today Bio. 2025; 31:101559.

PMID: 40026631 PMC: 11871467. DOI: 10.1016/j.mtbio.2025.101559.

Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.

Chen Y, Douanne N, Wu T, Kaur I, Tsering T, Erzingatzian A Sci Adv. 2025; 11(9):eads5249.

PMID: 40009680 PMC: 11864201. DOI: 10.1126/sciadv.ads5249.

Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.

References

Heijnen H, Schiel A, Fijnheer R, Geuze H, Sixma J . Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999; 94(11):3791-9. View

Skokos D, Le Panse S, Villa I, Rousselle J, Peronet R, David B . Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol. 2001; 166(2):868-76. DOI: 10.4049/jimmunol.166.2.868. View

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D . Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4(5):594-600. DOI: 10.1038/nm0598-594. View

Reynolds S, Zeleniuch-Jacquotte A, Shapiro R, Roses D, Harris M, Johnston D . Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res. 2003; 9(2):657-62. View

Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P . Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999; 147(3):599-610. PMC: 2151184. DOI: 10.1083/jcb.147.3.599. View

Denzer K, Kleijmeer M, Heijnen H, Stoorvogel W, Geuze H . Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000; 113 Pt 19:3365-74. DOI: 10.1242/jcs.113.19.3365. View

Johnstone R . The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem Cell Biol. 1992; 70(3-4):179-90. DOI: 10.1139/o92-028. View

Lamparski H, Patel S, Hsu D, Ruegg C, Le Pecq J . Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002; 270(2):211-26. DOI: 10.1016/s0022-1759(02)00330-7. View

Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C . Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303. DOI: 10.1038/85438. View

10.

Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker Jr S . American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2003; 22(2):330-53. DOI: 10.1200/JCO.2004.09.053. View

11.

Farsad K . Exosomes: novel organelles implicated in immunomodulation and apoptosis. Yale J Biol Med. 2002; 75(2):95-101. PMC: 2588725. View

12.

Garcia-Lora A, Algarra I, Garrido F . MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003; 195(3):346-55. DOI: 10.1002/jcp.10290. View

13.

Raposo G, Nijman H, Stoorvogel W, Liejendekker R, Harding C, Melief C . B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183(3):1161-72. PMC: 2192324. DOI: 10.1084/jem.183.3.1161. View

14.

Andre F, Schartz N, Movassagh M, Flament C, Pautier P, Morice P . Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329):295-305. DOI: 10.1016/S0140-6736(02)09552-1. View

15.

Massarelli E, Andre F, Liu D, Lee J, Wolf M, Fandi A . A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2002; 39(1):55-61. DOI: 10.1016/s0169-5002(02)00308-2. View

16.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

17.

Andre F, Chaput N, Schartz N, Flament C, Aubert N, Bernard J . Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004; 172(4):2126-36. DOI: 10.4049/jimmunol.172.4.2126. View

18.

Martinez-Lorenzo M, Anel A, Gamen S, Monle n I, Lasierra P, Larrad L . Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol. 1999; 163(3):1274-81. View

19.

Park J, Kwon T, Kim I, Sohn S, Kim Y, Il Kim C . A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods. 2002; 266(1-2):79-86. DOI: 10.1016/s0022-1759(02)00105-9. View

20.

Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino T, Sakata M . Detection of MAGE-4 protein in lung cancers. Int J Cancer. 1995; 64(3):158-65. DOI: 10.1002/ijc.2910640303. View